#United Kingdom #Clinical Trials #eCOA #Maidenhead #RWS

RWS Unveils New Linguistic Validation Service

In a significant advancement for the pharmaceutical and clinical research landscape, RWS, a leading AI solutions firm, has introduced a state-of-the-art eCOA (electronic clinical outcome assessment) translation and linguistic validation service. This initiative aims to facilitate pharmaceutical companies and clinical research organizations (CROs) in expediting their clinical trials through improved efficiency and reduced delays.

At the core of RWS's new offering is the unification of crucial services. The new model integrates COA licensing, source validation, multilingual translation, Trados-enabled eCOA migration, intelligent workflows, rater training, and dedicated program management. This comprehensive approach ensures end-to-end governance and accountability throughout the COA lifecycle

The timing in global clinical trials is critical, and language has traditionally been a significant hurdle. Each week saved can have profound impacts on the timeline and outcome of a clinical study. Sponsors often face the urgency to transition from instrument access to eCOA deployment without jeopardizing study initiation, site activation, or regulatory submissions. Many still juggle multiple vendors and disparate systems for managing licensing, translation, and training, which creates accountability gaps.

RWS's innovative service model tackles this challenge head-on. By centering upon dedicated program management and smart workflows, RWS ensures a single leadership team supervises every aspect of the project. From planning to communication and risk management, they handle all stages of development, ensuring a streamlined experience from licensing to global deployment.

Martial Marcotti, EVP and Chief Product Officer at Kayentis, one of the top eCOA vendors, praised the service, stating, "Bringing eCOA translation and rater training under one integrated team addresses the operational challenges sponsors encounter. This approach enhances execution across various studies and therapeutic areas. RWS recognizes both the pressures sponsors face and the quality benchmarks required in regulated research, making them a trusted ally in this domain."

Moreover, RWS has amplified its digital health solutions by incorporating rater training into their service package. This move integrates various elements like COA licensing and eCOA migration into a singular program, resulting in more efficient communication, improved governance, and seamless vendor management.

Dan Herron, Global VP of Digital Health at RWS, articulated the necessity for clinical teams to balance speed with quality. He remarked, "For over a decade, the industry has relied on piecemeal methods for services like licensing and rater training. However, our fresh approach, where every service is combined into one solution, enhances not only the pace but also the cohesiveness and scalability of study execution."

A key aspect of this innovation includes RWS’s investment in AI-driven tools and automation, which aim to bolster the contributions of subject matter experts while reducing manual workload. By automating repetitive tasks and enhancing quality control, RWS ensures research maintains its rigor and compliance with regulatory standards.

In conclusion, RWS's new linguistic validation service represents a crucial leap toward optimizing the clinical trial process. By unifying multiple services under one roof, they not only simplify the execution of global studies but also enhance the quality of patient experience and outcomes in research. Stakeholders interested in further information about how this new service can transform clinical trials can visit RWS's official website for more details.